HZNP News and Press, Horizon Therapeutics Public Limited Company From 03/12/23

-- Data presented at the North American Neuro-Ophthalmology Society ( NANOS ) Annual Meeting on March 11-16 in Orlando -- Horizon Therapeutics plc (Nasdaq: HZNP) today announced results of an analysis of real-world treatment with TEPEZZA in Thyroid Eye Disease (TED) patients...

2023-03-03 06:30:17 ET InvestorPlace - Stock Market News, Stock Advice & Trading Tips If searching out over-$100 stocks to buy seems arbitrary, take a step back and consider this. It’s great to have a mix of stocks in your portfolio. There are all sorts of sizes ...

Summary Soros' 13F portfolio value increased from $5.86B to $7.26B this quarter. The number of positions decreased from 270 to 208. Soros increased Alphabet and Tesla while decreasing Rivian, Amazon, Nike, T-Mobile, and Biohaven. Horizon Therapeutics at 4.48% of the portfolio is the...

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF SUCH JURISDICTION In accordance with Rule 2.12 of the Irish Takeover Panel Act, 1997, Takeover Rules, 2...

Summary My portfolio, built specifically for my retirement ~20+ years from now, features growth, dividends, and risk stocks for a happy retirement. Great performances by Meta and Tesla helped fuel another market beat in 2023 for me in February even disregarding depositing my 2022 IRA co...

Horizon Therapeutics press release ( NASDAQ: HZNP ): Q4 Non-GAAP EPS of $1.21 beats by $0.12 . Revenue of $942M (-6.7% Y/Y) beats by $19.05M . “2022 marked another impressive year for Horizon, with double-digit net sales growth across our commercial portfolio an...

Fourth-Quarter 2022 Results: -- Net Sales of $942.0 Million -- -- GAAP Net Income of $120.4 Million; Adjusted EBITDA of $ 357.5 Million ; Includes $37.3 Million of Acquired IPR&D and Milestones Expenses -- -- TEPEZZA ® (teprotumumab-trbw) Net...

Summary John Paulson’s 13F portfolio value decreased from $1.37B to $1.11B this quarter. Paulson & Company decreased AngloGold Ashanti while increasing Agnico Eagle Mines. The top three positions are at 47% of the portfolio. For further details see: ...

Horizon Therapeutics ( NASDAQ: HZNP ) is scheduled to announce Q4 earnings results on Wednesday, March 1st, before market open. The consensus EPS Estimate is $1.09 (-22.7% Y/Y) and the consensus Revenue Estimate is $922.95M (-8.6% Y/Y). Over the last 2 years, HZNP has beaten...

Summary Horizon Therapeutics Public Limited Company is a $25 billion biotech that's being acquired by Amgen Inc. The FTC has issued a 2nd request following a letter by Senator Elizabeth Warren. Warren raises a number of important issues but few that pertain specifically to this deal...